SAN FRANCISCO, Nov. 8 /PRNewswire/ -- Jennerex, Inc. today announced the addition of Mr. Robert A. Ingram as Special Advisor to the Chairman and to The President & CEO, and the hiring of Mr. Marty Glick as Executive Vice President, Corporate Strategy.
Bob Ingram is Vice Chairman, Pharmaceuticals at GlaxoSmithKline (plc), and previously served as Chief Executive Officer, Chief Operating Officer and President of Pharmaceutical operations for Glaxo Wellcome. Mr. Ingram is Chairman of the Board of Directors of OSI Pharmaceuticals, Inc. and Valeant Pharmaceuticals International, and a member of the Board of Directors of Allergan, Inc., Lowe's Companies, Edwards Lifesciences Corporation, and Wachovia Corporation.
"We are delighted to welcome Bob to the Jennerex team. His experience in leading companies which have successfully developed and commercialized major new medicines adds significant strategic depth to our team," said Brennan Mulcahy, Chairman of Jennerex.
"I am excited to work with the Board and CEO of Jennerex to develop and commercialize a new class of biotherapeutics for the treatment of several major types of cancer," said Bob Ingram.
"We know Bob's extensive pharmaceutical leadership experience will be invaluable to Jennerex as we leverage our innovative technology platform to develop and commercialize major new medicines to treat patients with serious unmet needs in oncology, including liver cancer, melanoma and lung cancer," said David H. Kirn, M.D., President and Chief Executive Officer.
Mr. Glick was Executive Vice President and Chief Financial Officer of
Theravance, Inc. until 2005. He led the efforts to successfully raise over
$350 million of private and public equity and to form an innovative
strategic alliance with GlaxoSmithKline. Prior to Theravance, Mr. Glick
held the position of Vice President Finance at Genentech Inc where he was
involved in structuring major deals such as in-licensing of Rituxan(R) from
|SOURCE Jennerex, Inc.|
Copyright©2007 PR Newswire.
All rights reserved